TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers at Albert Einstein College of Medicine report that restoring chaperone-mediated autophagy (CMA) reduced senescent-cell buildup and signs of inflammation and fibrosis in aged mice. The findings, published in Nature Aging, also include human lung-tissue analyses, but do not establish that the approach is safe or effective as a treatment in people.
Restoring a cellular protein-recycling process reduced the buildup of senescent cells and eased signs of lung fibrosis in aged mice, researchers at Albert Einstein College of Medicine report in a study published October 5 in Nature Aging. The findings point to a possible way to help immune cells clear these cells, but the experiments do not show that the approach works as a treatment in people.
The study focused on chaperone-mediated autophagy (CMA), a process in which specialized chaperone molecules identify selected proteins for breakdown and recycling. The researchers found that CMA activity declined with age in both senescent cells and macrophages, immune cells that can engulf and remove unwanted cells. The team also analyzed human lung tissue, which the report says offers evidence that the findings may be relevant to people; it does not establish a clinical benefit.
In mouse wound-healing experiments, animals whose macrophages had been genetically altered to lack CMA accumulated more senescent cells at wound sites and healed more slowly than control mice. In laboratory experiments, fibroblasts from young mice increased CMA activity after being made senescent, while cells from old mice did not. The older cells accumulated proteins that were not properly broken down and released substances that, according to the researchers, encouraged nearby healthy cells to become senescent and made macrophages less able to recognize and remove them.
The researchers also tested CA77.1, a small-molecule CMA activator they had previously developed. In aged mice, five months of daily oral treatment was associated with fewer senescent cells in several organs and reduced signs of inflammation and fibrosis. In a separate laboratory test, CA77.1 treatment restored the ability of macrophages isolated from aged mice to engulf particles to levels comparable with macrophages from young mice. These results come from animal and cell experiments, not a human treatment trial.
A Different Route to Clearing Senescent Cells
Senescent cells stop dividing but remain alive, and their secretions can affect surrounding tissue. They can serve a useful role in processes such as wound repair, where they help recruit cells involved in healing; problems may arise when they persist. The study suggests that age-related changes may weaken both sides of the cleanup process: senescent cells can release harmful material, while macrophages may become less effective at removing them.
That framing matters because it points beyond simply killing senescent cells. The researchers’ proposed approach would restore CMA in both the cells that accumulate and the macrophages tasked with clearing them. The mouse results suggest this could address more than one part of the process, but whether that strategy can prevent or treat age-related disease in people remains untested in the evidence described.
The findings may also affect how researchers evaluate senolytic drugs, which are designed to eliminate senescent cells. The team cautions that cells made senescent in the laboratory using material from young animals may not represent the behavior of senescent cells in older bodies. This is a research implication, not evidence that existing senolytic treatments are ineffective.
As an affiliate, we earn on qualifying purchases.
How Aging Affects Cellular Cleanup
CMA is one form of cellular maintenance: it selectively directs particular proteins for breakdown rather than indiscriminately digesting cell contents. Previous work by study leader Ana Maria Cuervo and colleagues found that CMA activity declines with age and that reduced activity can allow cellular waste to accumulate. The new report examines whether that decline also affects senescent cells and the immune response that removes them.
Senescent cells are sometimes called “zombie cells” because they remain in tissues after stopping normal division. The nickname is informal; the scientific term is senescent cells. Their role is not uniformly harmful: they can contribute to wound repair, but lingering cells and their secretions have been linked to chronic inflammation and age-related disease. The study tested this relationship mainly in mice and also examined human lung tissue.
Human Benefits Remain Unproven
The reported reductions in senescent-cell buildup and fibrosis came from aged-mouse experiments. The source material does not describe a clinical trial testing CA77.1 in people, nor does it establish a safe dose, possible side effects, or whether the compound would produce the same effects in humans. Human lung-tissue analysis supports possible relevance but cannot by itself show that activating CMA improves patients’ health.
The report identifies idiopathic pulmonary fibrosis (IPF) as a potential human disease setting for follow-up, but the supplied account ends before detailing the findings of that part of the research. The size and scope of the human tissue analysis, the duration of any effects, and whether the results apply to other age-related conditions are not specified in the material provided.
Testing Relevance to Lung Disease
The researchers’ next step is to determine whether the findings have relevance to a human disease associated with aging. The study report identifies idiopathic pulmonary fibrosis as a candidate, but the available source material does not provide the full results of that analysis. Further work would be needed to establish how CMA activity relates to the disease in people.
Before CA77.1 could be considered for clinical use, researchers would also need to test its safety and effects in people through appropriately designed studies. For now, the work offers a preclinical research direction: investigate whether restoring CMA can improve the interaction between senescent cells and the immune cells that clear them.
Key Questions
What did the study find?
Researchers reported that restoring chaperone-mediated autophagy reduced senescent-cell buildup and signs of inflammation and fibrosis in aged mice. They also found that CMA activity affected macrophages’ ability to clear senescent cells.
What are senescent cells?
Senescent cells are cells that have stopped dividing but remain alive. They can have useful roles, including during wound healing, but persistent senescent cells may release substances that affect nearby tissue.
Was CA77.1 tested in people?
The source report describes experiments in aged mice and tests using macrophages isolated from mice. It does not report a human clinical trial of CA77.1.
Does this mean a treatment for lung fibrosis is available?
No. The findings are preclinical and do not show that activating CMA treats lung fibrosis in people. Human safety and effectiveness would need to be established in further research.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
